NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Trillium Therapeutics Inc (TO: TRIL)
TRIL Technical Analysis
4
As on 19th Nov 2021 TRIL STOCK Price closed @ 23.33 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 14.74 & Buy for SHORT-TERM with Stoploss of 19.20 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TRILSTOCK Price
Open | 23.22 | Change | Price | % |
High | 23.45 | 1 Day | 0.11 | 0.47 |
Low | 23.22 | 1 Week | 1.06 | 4.76 |
Close | 23.33 | 1 Month | 0.93 | 4.15 |
Volume | 60423 | 1 Year | 5.17 | 28.47 |
52 Week High 26.40 | 52 Week Low 7.51 |
TO Canada Most Active Stocks
YRI | 7.89 | 0.13% |
UEX | 0.50 | 16.28% |
RY | 172.33 | % |
CVE | 22.94 | % |
BNS | 72.78 | % |
TD | 77.32 | % |
SJR-B | 40.48 | 0.02% |
BMO | 129.54 | % |
MFC | 41.89 | % |
FCU | 0.92 | % |
TO Canada Top Gainers Stocks
TO Canada Top Losers Stocks
TRIL Daily Charts |
TRIL Intraday Charts |
Whats New @ Bazaartrend |
TRIL Free Analysis |
|
TRIL Important Levels Intraday
RESISTANCE | 23.77 |
RESISTANCE | 23.63 |
RESISTANCE | 23.54 |
RESISTANCE | 23.46 |
SUPPORT | 23.20 |
SUPPORT | 23.12 |
SUPPORT | 23.03 |
SUPPORT | 22.89 |
TRIL Forecast October 2024
4th UP Forecast | 45.14 |
3rd UP Forecast | 38.15 |
2nd UP Forecast | 33.82 |
1st UP Forecast | 29.5 |
1st DOWN Forecast | 17.16 |
2nd DOWN Forecast | 12.84 |
3rd DOWN Forecast | 8.51 |
4th DOWN Forecast | 1.52 |
TRIL Weekly Forecast
4th UP Forecast | 27.63 |
3rd UP Forecast | 26.25 |
2nd UP Forecast | 25.40 |
1st UP Forecast | 24.55 |
1st DOWN Forecast | 22.11 |
2nd DOWN Forecast | 21.26 |
3rd DOWN Forecast | 20.41 |
4th DOWN Forecast | 19.03 |
TRIL Forecast2024
4th UP Forecast | 61.18 |
3rd UP Forecast | 49.04 |
2nd UP Forecast | 41.54 |
1st UP Forecast | 34.03 |
1st DOWN Forecast | 12.63 |
2nd DOWN Forecast | 5.12 |
3rd DOWN Forecast | -2.38 |
4th DOWN Forecast | -14.52 |
Trillium Therapeutics Inc ( TO Canada Symbol : TRIL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
TRIL Other Details
Segment | EQ | |
Market Capital | 2337188608.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
TRIL Address
TRIL Latest News
TRIL Business Profile
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Cambridge, Massachusetts. Address: 2488 Dunwin Drive, Mississauga, ON, Canada, L5L 1J9
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service